- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03042286
SAPhIRE Statin Adverse Drug Reaction (STATIN)
Study of Pharmacogenomic and Pharmacokinetic Risk Factors Associated With Statin Induced Muscle ADRs (Adverse Drug Reactions) in Singapore Population
To find out the pharmacokinetic and genetic risk factors involved in muscular side effects (myalgia) associated with statin therapy. To learn better ways of identifying risk factors associated with muscle side effects during statin therapy. To perform laboratory analysis to identify factors predicting future outcomes. The genetic material, in combination with other medical information and blood tests, will be available to researchers studying genetic and other factors that contribute to myalgia caused in some patient population on statin medication.
Patients on statin are selected for this study. This study will recruit 1500 subjects from National heart Centre Singapore over a period of 2.5 years.
Participation in the full study includes the donation of genetic material. However, subjects have the option of not having blood subjected to genetic analysis and still participate in the study. In this case, blood samples will only be analyzed for the statin drug content.
Study Overview
Status
Conditions
Detailed Description
Objective is to characterize the relationship between genetic polymorphisms and inter-individual variability in plasma statin and metabolite concentration(s) and to quantify its contribution towards clinically significant statin induced muscle ADR phenotypes myopathy and/or myalgia in Singapore population. Methodology: This research involves the study of two different kinds of muscle ADRs commonly associated with statin therapy, namely myalgia and myopathy. The study of myalgia will include the recruitment and sample collection (blood)from 3000 subjects from the outpatient clinic at NUH and NHC, who are on either simvastatin or atorvastatin. To identify genetic variants associated with altered stain exposure, investigators will perform an analysis of the drug and metabolite levels in plasma, followed by a genetic analysis of DNA from the blood samples of the recruited subjects. A subgroup of 30 subjects (15 from NUH and 15 from NHC) from this large cohort will be used to study intra-subject variability in statin drug and metabolite exposure. The genetic association analysis of genotype and statin blood measurements will be done using liner regression analysis. To test the hypothesis that related pharmacokinetic variants are associated with myalgia and myopathy, investigators will perform the case-control association analysis using logistic regression to examine the frequency of genetic variant in patients with clinically identified ADRs and compare it to control subjects without any ADRs. A separate cohort of 200 subjects will be recruited for the myopathy study through the NUH outpatient clinic following subject identification through an IRB approved medical records review of patients who were/are any statin drug/dose. Blood samples collected from these patients will be subjected to genetic analysis to identify genetic variants associated with symptomatic phenotypes.
Potential Benefits and risks: The potential benefits of this study include, identifying strong risk factors of statin induced muscle symptoms myalgia/myopathy that should inform clinical practice in minimizing/ managing severity of statin associated muscle symptoms, by identifying patient populations with an increased risk to statin induced myalgia and/or myopathy. This information might ultimately inform treatment decisions including drug selection and dosing and improved prediction of treatment response in a heterogeneous population. The only possible risk in the study is that associated with blood-taking. Obtaining blood can cause pain, bleeding, bruising, or swelling at the site of the needle stick. Fainting sometimes occurs and infection rarely occurs.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Dr Wei Chieh Jack Tan
- Phone Number: 67048892
Study Contact Backup
- Name: Katherina Oh
- Phone Number: 67042290
Study Locations
-
-
-
Singapore, Singapore, 169609
- Recruiting
- National Heart Centre Singapore
-
Contact:
- Dr Wei Chieh Jack Tan
- Phone Number: 67048892
-
Contact:
- Katherina Oh
- Phone Number: 67042290
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
For myopathy cohort:
- Subjects are/were on any statin drugs at any dose
- Subjects reported/ diagnosed with myopathy =10X normal CK levels
- Myopathy in subjects were statin induced
For myalgia cohort:
- Subjects are on either Simvastatin or Atorvastatin
- If subject experience muscle symptoms without CK elevation (myalgia), it should be statin induced
- Compliance to five consecutive statin doses prior to sample collection
For the myalgia subgroup (n=30) for intra-individual variability assessment:
- Subjects are on either Simvastatin or Atorvastatin
- If subject experience muscle symptoms without CK elevation (myalgia), it should be statin induced
- Subjects are willing to provide two blood samples during each of the 3 separate visits
- Compliance to five consecutive statin doses prior to sample collection
Exclusion Criteria:
- 1. Unable or unwilling to give written informed consent 2. Subjects who are pregnant or breast feeding
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Statin drug and metabolite measurement
Time Frame: 3 to 6 hours
|
Multiple reaction monitoring via a triple quadropole mass spectrometry (MS) platform
|
3 to 6 hours
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pharmacogenomics associated with statin
Time Frame: 3 to 6 hours
|
DNA extraction will be performed at GIS using Qiagen QIAamp DNA Blood Maxi kit and will be quantified by pico-green serial dilution assays
|
3 to 6 hours
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Dr Wei Chieh Jack Tan, National Heart Centre Singapore
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2014/00856
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Myopathy
-
Newcastle-upon-Tyne Hospitals NHS TrustRecruitingX-linked Myotubular Myopathy | Centronuclear Myopathy | Myotubular Myopathy | Myotubular Myopathy 1 | Myotubular (Centronuclear) Myopathy | Centronuclear Myopathy, X-LinkedUnited Kingdom
-
Clinic for Special ChildrenRecruitingMyopathy | Myopathy; Hereditary | Myopathies, Nemaline | TNNT1-associated Myopathy | Infantile-onset Nemaline Rod Myopathy | Myopathy, Rod | Amish Nemaline Myopathy | Nemaline Myopathy 5 | NEM5 | Genetic Muscle Disease | Recessive Hereditary Disorder (Autosomal) | ANMUnited States
-
Vastra Gotaland RegionEnrolling by invitationMusculoskeletal Diseases | Neuromuscular Diseases | Centronuclear Myopathy | Nemaline Myopathy | Congenital Myopathy | Myosin Storage MyopathySweden
-
Ultragenyx Pharmaceutical IncTerminatedHereditary Inclusion Body Myopathy | GNE Myopathy | Inclusion Body Myopathy 2 | Distal Myopathy With Rimmed Vacuoles | Distal Myopathy, Nonaka Type | Quadriceps Sparing MyopathyCanada, United States, Bulgaria
-
James DowlingCanadian Institutes of Health Research (CIHR); Cures Within Reach; The Joshua... and other collaboratorsRecruitingX Linked Myotubular MyopathyUnited Kingdom, Canada, United States
-
Radboud University Medical CenterUMC UtrechtNot yet recruitingCentronuclear Myopathy | Nemaline Myopathy | Central Core Disease | Multi-Minicore DiseaseNetherlands
-
Ultragenyx Pharmaceutical IncTerminatedHereditary Inclusion Body Myopathy | GNE Myopathy | Distal Myopathy With Rimmed Vacuoles | Distal Myopathy, Nonaka Type | Quadriceps Sparing MyopathyUnited States, Canada, United Kingdom, Israel, Italy, Bulgaria, France
-
Astellas Gene TherapiesCompletedX-linked Myotubular MyopathyUnited States, France, United Kingdom, Canada, Germany
-
University of FloridaAudentes TherapeuticsCompletedX-linked Myotubular MyopathyUnited States
-
Rigshospitalet, DenmarkActive, not recruitingCongenital Myopathy | Inherited Muscle Diseases | RYR1-myopathyDenmark